Get the Stockscreener App
1.95
3.17%
0.06
After Hours:
1.96
0.01
+0.51%
Innate Pharma Adr stock is traded at $1.95, with a volume of 11,208.
It is up +3.17% in the last 24 hours and down -6.70% over the past month.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
See More
Previous Close:
$1.89
Open:
$1.93
24h Volume:
11,208
Relative Volume:
0.06
Market Cap:
$179.76M
Revenue:
$47.04M
Net Income/Loss:
$-63.98M
P/E Ratio:
-2.4182
EPS:
-0.8064
Net Cash Flow:
$-34.39M
1W Performance:
+7.14%
1M Performance:
-6.70%
6M Performance:
-8.88%
1Y Performance:
+30.00%
1-Day Range:
$1.93
$1.98
1-Week Range:
$1.795
$1.98
52-Week Range:
$1.41
$3.5107
Innate Pharma Adr Stock (IPHA) Company Profile
Compare IPHA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPHA
Innate Pharma Adr
|
1.95 | 174.20M | 47.04M | -63.98M | -34.39M | -0.8064 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Innate Pharma Adr Stock (IPHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-18-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-28-25 | Initiated | BTIG Research | Buy |
| Sep-03-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-15-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-24-20 | Initiated | Goldman | Neutral |
View All
Innate Pharma Adr Stock (IPHA) Latest News
Earnings call transcript: Innate Pharma Q3 2025 shows innovation progress - Investing.com
Innate Pharma Q3 2025 slides: Lacutamab progress highlighted amid clinical advances - Investing.com India
Innate Pharma Q3 2025 slides: Lacutamab progress highlighted amid clinical advances By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q3 2025 shows innovation progress By Investing.com - Investing.com UK
Disney, Brookfield, Nu Holdings and more set to report earnings Thursday - Investing.com UK
Pre Market Movers: SLRX, SI, ELDN Swing Big - RTTNews
Innate Pharma stock soars after FDA clears path for Phase 3 trial - Investing.com
Innate Pharma (IPHA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - MSN
Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer - GlobeNewswire Inc.
Innate Pharma FY2025 EPS Forecast Increased by HC Wainwright - MarketBeat
Innate Pharma (NASDAQ:IPHA) Stock Price Down 3.9%Time to Sell? - MarketBeat
Lucid Capital Markets initiates coverage on Innate Pharma stock with Buy rating - Investing.com India
Goldman Sachs Sticks to Their Hold Rating for Innate Pharma SA (IPHYF) - Barchart.com
Leerink Partnrs Forecasts Innate Pharma Q3 Earnings - Defense World
Innate Pharma FY2025 EPS Estimate Increased by HC Wainwright - MarketBeat
Innate Pharma (NASDAQ:IPHA) Downgraded by HC Wainwright to “Neutral” - Defense World
Innate Pharma (NASDAQ:IPHA) Given “Market Perform” Rating at Leerink Partners - Defense World
Leerink Partners downgrades Innate Pharma stock on shift to ADC strategy - Investing.com
Innate Pharma SA Reports First Half 2025 Financial Results - TipRanks
Innate Pharma H1 2025 slides: strategic refocus on key assets extends cash runway By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma’s Q2 2025 focus on strategic assets - Investing.com
Innate Pharma H1 2025 slides: strategic refocus on key assets extends cash runway - Investing.com
Innate Pharma Reports First Half 2025 Business Update and Financial Results - Placera.se
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Short Interest Down 25.8% in August - MarketBeat
Innate Pharma (NASDAQ:IPHA) Trading 1.7% HigherWhat's Next? - MarketBeat
Innate Pharma (NASDAQ:IPHA) Trading 1.7% Higher – Here’s What Happened - Defense World
Arm Holdings PLC Releases Q2 2025 Financial Report Amid Market Challenges - The Globe and Mail
How strong is Innate Pharma S.A. Depositary Receipt company’s balance sheetSuperior risk-adjusted returns - Jammu Links News
Innate Pharma stock initiated with Buy rating at BTIG on cancer therapy potential - Investing.com
Innate Pharma (NASDAQ:IPHA) Trading 1.7% Higher – What’s Next? - Defense World
Exchange Traded Concepts LLC Has $112,000 Stock Position in Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) - Defense World
Why Kingsoft Cloud Holdings Stock Plummeted by Nearly 8% Today - The Globe and Mail
Should You Buy, Hold, or Sell PDD Holdings Stock Before Q1 Earnings? - The Globe and Mail
Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook - Investing.com
Innate Pharma reports promising preclinical results for cancer drug IPH4502 - Investing.com
What Are Earnings Reports? - MarketBeat
Earnings call: Innate Pharma Q3 2024 results highlight oncology pipeline - Investing.com
AZN Stock Price and Chart — NASDAQ:AZN - TradingView
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study - Nasdaq
What is the current Price Target and Forecast for Innate Pharma (IPHA) - Zacks Investment Research
Innate, Sanofi ink licensing deal for NK cells - MarketWatch
Senti Biosciences (SNTI) Short Interest & Short Float | Updated Nov 2025 - MarketBeat
Innate Pharma: AstraZeneca To Discontinue INTERLINK-1 Monalizumab Combination Trial - Nasdaq
Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins - Equities.com
Annovis Bio (ANVS) Short Interest Ratio and Volume 2025 - MarketBeat
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - FinancialContent
Mersana Therapeutics (MRSN) Short Interest & Short Float | Updated Nov 2025 - MarketBeat
MariMed (MRMD) Short Interest Ratio and Volume 2025 - MarketBeat
Karyopharm Therapeutics (KPTI) Short Interest Ratio and Volume 2025 - MarketBeat
Innate Pharma Adr Stock (IPHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):